Healthcare reform
The United States spends more on health care than any other wealthy country, yet leaves tens of millions uninsured or underinsured and records worse population-health outcomes on several basic measures. That mismatch—high prices, fragmented coverage, and middling results—is why reform stays on the agenda even after the Affordable Care Act, pandemic-era subsidies, and successive administrations’ incremental changes.
Options range from tightening the current hybrid system to replacing private insurance with a government payer. They differ on who pays, who chooses, how prices are set, and how much disruption people and providers would accept.
What the current system looks like
The U.S. system is a patchwork: employer-sponsored insurance covers a majority of non-elderly Americans; Medicare covers most people 65 and older; Medicaid and CHIP cover many low-income children and adults (unevenly by state); ACA marketplaces and other individual plans cover people who buy their own insurance; and the VA and other programs cover specific groups.
In 2025, about 26.7 million people—7.9 percent of the population—were uninsured for the full year, near historic lows after the ACA and temporary subsidy expansions. Employment-based coverage remained the largest source. Public coverage (Medicare plus Medicaid) covered more than a third of the population.
Costs are high and rising. National health spending is in the high teens as a share of GDP—roughly twice the OECD average—and per-person spending far exceeds peer countries. A modeled family of four under employer coverage was estimated at about $37,800 in 2026 in one industry index; employer family premiums have been approaching or exceeding $30,000 in other analyses.
Outcomes do not match the spending. Life expectancy is around 79 years, below the OECD average. The U.S. has high rates of avoidable deaths, fewer primary-care physicians per capita than many peers, and a large share of people who skip care because of cost. Hospitals, physician prices, pharmaceuticals, administrative complexity, and consolidation all contribute; utilization is not uniformly higher than in other rich countries.
Policy in 2025–2026 added new pressure. Enhanced ACA premium tax credits expired at the end of 2025. Marketplace effectuated enrollment fell from a peak near 22 million toward the high teens; net premiums and deductibles rose sharply for many remaining enrollees. Broader legislation also changed Medicaid eligibility and work-reporting rules, with CBO-style projections of millions more uninsured over a decade depending on implementation.
That is the baseline reformers are arguing about: high prices, incomplete coverage, heavy administrative load, and political disagreement over whether the problem is too little government, too much government, or poorly designed markets.
Incremental reforms that keep the current architecture
One family of options keeps employer coverage, Medicare, Medicaid, and regulated private markets, then changes the rules around the edges.
Strengthen the ACA. Restore or redesign premium tax credits, improve cost-sharing subsidies, add reinsurance, close the Medicaid “coverage gap” in non-expansion states, and tighten or loosen rules on short-term and other lightly regulated plans. Advocates say this is the least disruptive path to near-universal coverage. Critics say it locks in high underlying prices and leaves people dependent on annual subsidy fights.
Public option or Medicare/Medicaid buy-in. A government-run plan would compete with private insurers on the exchanges, or working-age people could buy into Medicare (or a Medicare-like product) at an actuarially fair premium. Some versions use Medicare payment rates to force lower prices; others negotiate separately. States such as Washington and Colorado already run limited “public option” products on their exchanges. Results are mixed: enrollment has grown in some years, premium effects vary by market, and critics argue reinsurance and other policies explain more of the savings than the public plan itself.
Price and middleman rules. Site-neutral Medicare payments, hospital price caps or growth limits in concentrated markets, stronger surprise-billing enforcement, pharmacy-benefit-manager (PBM) reforms, and expanded drug-price negotiation all aim at unit prices rather than who holds the insurance card. CMS has also proposed expanding accountable care organizations, shifting clinicians off traditional MIPS reporting, and giving insurers more flexibility on plan design (including multi-year catastrophic products).
These steps can be combined. They do not require eliminating private insurance. They also do not automatically produce European-level prices; providers and manufacturers can shift costs, and political resistance to rate-setting is strong.
Single-payer and “Medicare for All”
Medicare for All would replace most private insurance and many public programs with one national insurance program financed by taxes instead of premiums. Typical bills cover a broad benefit package, often with little or no cost-sharing, and restrict private insurers to supplemental coverage.
Supporters argue that a single payer would cut administrative waste (traditional Medicare’s overhead is far lower than private insurers’), give the government leverage to set hospital and drug prices, and guarantee coverage independent of job or income. CBO analyses of single-payer designs found that federal spending would rise by a very large amount—on the order of $1.5 trillion to $3 trillion a year in later years under older scoring—while national health spending could fall or rise depending on payment rates, cost-sharing, and whether long-term care is included. Administrative savings and lower prices pull spending down; extra utilization from better coverage pulls it up.
Critics focus on three issues. First, financing: replacing premiums with taxes is a huge fiscal and political shift; payroll or income taxes large enough to fund comprehensive benefits would be visible and contested. Second, supply: if prices are cut toward current Medicare rates while demand rises, CBO and others have warned of longer waits and provider shortages unless capacity expands. Third, transition: tens of millions of people like their current employer plans, and hospitals and physicians depend on commercial rates that are much higher than Medicare.
State single-payer attempts (Vermont’s abandoned Green Mountain Care, Colorado’s 2016 ColoradoCare ballot measure) failed on cost, tax design, or federal-law constraints. That does not prove a federal program is impossible; it shows the political and fiscal bar is high.
A softer cousin is a public option that grows over time—employers and individuals can buy in—so private coverage shrinks by choice rather than by ban. That is closer to what some Democrats have sketched as a 2029 playbook than an immediate single-payer switch.
Market-oriented and consumer-directed reforms
A different school treats the core problem as distorted prices and third-party payment, not the absence of a government insurer.
Typical tools include:
Larger health savings accounts (HSAs), individual coverage HRAs (ICHRAs) so employers give workers a defined contribution instead of a defined plan, and direct primary care.
Deregulating insurance design: more catastrophic and multi-year plans, fewer mandated benefits, interstate or association sales, and short-term plans with fewer ACA rules.
Sending subsidy dollars to people rather than to insurers (a theme of the administration’s “Great Healthcare Plan” rhetoric in 2026).
Aggressive price transparency so patients can shop; recognition of drugs already approved in peer countries; and fewer prescription-only rules for some medications.
Competition policy against hospital and insurer consolidation.
Advocates point to the large gap between U.S. commercial prices and Medicare or international prices, and to evidence that heavily regulated individual-market rules raised premiums for many buyers. They argue that people with “skin in the game” and real prices would use care more carefully and force providers to compete.
Critics reply that shopping works poorly for emergencies, complex illness, and concentrated hospital markets; that skinnier plans shift risk onto sick people; and that the uninsured and underinsured already ration care in ways that show up as worse outcomes. They also note that much of the U.S. cost problem is on the provider side (hospital systems, specialty care, drugs), not only on insurers.
Hybrid ideas exist: catastrophic public coverage plus large HSAs; premium support (a voucher to buy a private or public plan); or Medicare Advantage–style managed care as the default for more of the publicly financed population.
Delivery, prevention, and the parts insurance design cannot fix
Insurance reform does not automatically fix obesity, diabetes, maternal mortality, rural hospital closures, primary-care shortages, or prior-authorization friction. Parallel options include:
Paying more for primary care and prevention and less for high-margin procedures.
Value-based payment and ACOs (already expanding in Medicare).
Workforce pipeline, scope-of-practice, and telehealth rules.
Hospital global budgets or all-payer rate setting (Maryland is the main U.S. experiment).
Public-health and social-determinant investments that sit outside the medical-claims system.
Hospitals remain the largest slice of the dollar; drugs are a smaller but fast-growing and politically salient slice. Any serious cost strategy eventually collides with those two sectors.
Trade-offs that do not go away
Every option trades one goal against another:
GoalTypical tensionUniversal coverageTaxes, mandates, or auto-enrollment vs. individual choiceLower national spendingLower provider prices and utilization vs. access and innovationLower household premiumsHigher deductibles, narrower networks, or higher taxesProvider incomesCommercial rates that fund capacity vs. public rates that constrain budgetsAdministrative simplicitySingle rules vs. tailored private productsPolitical durabilityIncremental change that survives elections vs. structural change that invites repeal
International comparisons are useful but incomplete. Other OECD countries achieve lower spending and broader coverage with different mixes of social insurance, tax finance, global budgets, and private supplemental markets—and with different malpractice, wage, and demographic contexts. Copying a label (“single payer,” “all-payer,” “managed competition”) without the payment rates and political institutions that go with it is how reform slogans outrun implementation.
What “reform” will actually be decided by
Near-term U.S. policy is more likely to be a stack of incremental pieces than a replacement of the whole system: subsidy design, Medicaid rules, Medicare payment updates, drug negotiation, transparency, prior-auth limits, and state experiments. Structural options—national public option, Medicare buy-in, or single payer—remain live in Democratic planning documents and activist platforms; market and consumer-directed options remain live in Republican and administration proposals. Midterm and presidential calendars will decide which stack gets a majority.
The facts that constrain all of them are stubborn. Prices in the commercial sector are high. Coverage is still incomplete and is sensitive to subsidy design. Public programs already pay a large share of the bill and will grow with aging. No option eliminates scarcity; it only changes who waits, who pays, and who decides.
